24 May 2013
Keywords: lilly, licenses, raloxifene, chugai, eli, licensed, its
Article | 18 December 1995
Eli Lilly has licensed its estrogen receptor modulator, raloxifene, to
Chugai for codevelopment and comarketing in the Japanese market. The
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 December 1995
4 December 1995
© 2013 thepharmaletter.com